S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
TSE:HLS

HLS Therapeutics (HLS) Price Target & Analyst Ratings

C$4.83
-0.48 (-9.04%)
(As of 08/11/2023 08:50 PM ET)
Compare
Today's Range
C$4.83
C$5.35
50-Day Range
C$4.26
C$6.86
52-Week Range
C$4.12
C$13.25
Volume
43,144 shs
Average Volume
28,092 shs
Market Capitalization
C$156.25 million
P/E Ratio
N/A
Dividend Yield
4.14%
Price Target
C$13.83

HLS Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 1 Analyst Ratings

Consensus Analyst Price Target

C$13.83
186.40% Upside
High PredictionC$17.50
Average PredictionC$13.83
Low PredictionC$9.00
TypeCurrent
8/14/22 to 8/14/23
1 Month Ago
7/15/22 to 7/15/23
3 Months Ago
5/16/22 to 5/16/23
1 Year Ago
8/14/21 to 8/14/22
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$13.83C$19.80C$19.80C$27.80
Predicted Upside186.40% Upside51.09% Upside51.09% Upside106.17% Upside
Get HLS Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.


HLS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HLS Therapeutics Stock vs. The Competition

TypeHLS TherapeuticsMedical Companies
Consensus Rating Score
2.00
2.65
Consensus RatingHoldModerate Buy
News Sentiment RatingNegative News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/11/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$18.00 ➝ C$15.00+194.12%
7/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket PerformC$10.00 ➝ C$9.00+45.87%
3/17/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$21.75 ➝ C$17.50+175,000,000.00%
(Data available from 8/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HLS Price Target - Frequently Asked Questions

What is HLS Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for HLS Therapeutics stock is Hold based on the current 1 hold rating for HLS. The average twelve-month price prediction for HLS Therapeutics is C$13.83 with a high price target of C$17.50 and a low price target of C$9.00. Learn more on HLS's analyst rating history.

Do Wall Street analysts like HLS Therapeutics more than its competitors?

Analysts like HLS Therapeutics less than other Medical companies. The consensus rating for HLS Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how HLS compares to other companies.

Does HLS Therapeutics's stock price have much upside?

According to analysts, HLS Therapeutics's stock has a predicted upside of 137.96% based on their 12-month price targets.

What analysts cover HLS Therapeutics?

HLS Therapeutics has been rated by Raymond James, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (TSE:HLS) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -